



11 Publication number:

**0 401 384**  
**A1**

12

**EUROPEAN PATENT APPLICATION**  
**published in accordance with Art.**  
**158(3) EPC**

21 Application number: 90900360.0

 51 Int. Cl.<sup>5</sup>: **C07K 13/00, C07K 3/08,**  
**A61K 37/02**

22 Date of filing: 22.12.89

 86 International application number:  
**PCT/JP89/01292**

 87 International publication number:  
**WO 90/06952 (28.06.90 90/15)**

 30 Priority: 22.12.88 JP 324747/88  
 31.07.89 JP 199176/89

 43 Date of publication of application:  
 12.12.90 Bulletin 90/50

 84 Designated Contracting States:  
**AT BE CH DE ES FR GB IT LI LU NL SE**

 71 Applicant: **Kirin-Amgen, Inc.**  
**1900 Oak Terrace Lane**  
**Thousand Oaks California 91320(US)**

 72 Inventor: **ISHIKAWA, Rika**  
**36-2, Takagi 1-chome Higashiyamato-shi**  
**Tokyo 189(JP)**  
 Inventor: **OKADA, Yuji**  
**391, Kamikoide-machi Maebashi-shi**  
**Gunma-ken 371(JP)**  
 Inventor: **KAKITANI, Makoto**  
**391, Kamikoide-machi Maebashi-shi**  
**Gunma-ken 371(JP)**

 74 Representative: **Brown, John David**  
**FORRESTER & BOEHMERT**  
**Widenmayerstrasse 4/1**  
**D-8000 München 22(DE)**

 54 **CHEMICALLY MODIFIED GRANULOCYTE COLONY STIMULATING FACTOR.**

EP 0 401 384 A1  
 57 This invention provides a chemically modified protein prepared by combining polyethylene glycol with a polypeptide having substantially the following amino acid sequence and comprising the product of manifestation by a host cell of a foreign DNA sequence (1), wherein n is 0 or 1. This protein has a more lasting action of increasing neutrophils than that of the human granulocyte colony stimulating factor (G-CSF) known heretofore.

**BEST AVAILABLE COPY**